---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-072646"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:45:36.388651+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eliem Therapeutics Announces CFO Resignation and Appoints New Principal Financial and Accounting Officers

## Summary
- Erin Lavelle resigned as EVP, COO, and CFO effective March 10, 2023.
- Andrew Levin, Executive Chairman, appointed as principal financial officer (in addition to principal executive officer).
- Emily Pimblett, Chief Accounting Officer, appointed as principal accounting officer.
- Levin is a co-founder and managing director at RA Capital Management; Pimblett previously held roles at DomainTools and Avvo.

## SEC filing metadata
- accession: 0001193125-23-072646
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/0001193125-23-072646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/d461584d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-072646
- JSON: https://secwatch.observer/filing/0001193125-23-072646.json
- Plain text: https://secwatch.observer/filing/0001193125-23-072646.txt

## Key facts
- Executive change
  Andrew Levin was appointed as principal financial officer at Climb Bio, Inc..
  - Action: appointed
  - Role: principal financial officer
  source text: Effective as of March 10, 2023 (the “Transition Date”), the Board appointed (i) Andrew Levin, Executive Chairman, as the Company’s new principal financial officer (in addition to principal executive officer)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/0001193125-23-072646-index.htm
- Executive change
  Emily Pimblett was appointed as principal accounting officer at Climb Bio, Inc..
  - Action: appointed
  - Role: principal accounting officer
  source text: and (ii) Emily Pimblett, Chief Accounting Officer, as the Company’s principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/0001193125-23-072646-index.htm
- Executive change
  Erin Lavelle resigned as Executive Vice President, Chief Operating Officer and Chief Financial Officer at Climb Bio, Inc..
  - Action: resigned
  - Role: Executive Vice President, Chief Operating Officer and Chief Financial Officer
  source text: the Company and Erin Lavelle mutually agreed that Ms. Lavelle would resign as Executive Vice President, Chief Operating Officer and Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/0001193125-23-072646-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.